Advertisement
Canada markets closed
  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     
  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     
  • DOW

    37,986.40
    +211.02 (+0.56%)
     
  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     
  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     
  • Bitcoin CAD

    88,049.16
    +2,743.76 (+3.22%)
     
  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     
  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     
  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     
  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     
  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     
  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Top Ranked Value Stocks to Buy for January 21st

Here are three stocks with buy rank and strong value characteristics for investors to consider today, January 21st:

UnitedHealth Group Incorporated (UNH): This diversified health company has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 0.3% over the last 60 days.

UnitedHealth Group Incorporated Price and Consensus

UnitedHealth Group Incorporated Price and Consensus
UnitedHealth Group Incorporated Price and Consensus

UnitedHealth Group Incorporated price-consensus-chart | UnitedHealth Group Incorporated Quote

UnitedHealth has a price-to-earnings ratio (P/E) of 18.15 compared with 33.60 for the industry. The company possesses a Value Score of B.

ADVERTISEMENT

UnitedHealth Group Incorporated PE Ratio (TTM)

UnitedHealth Group Incorporated PE Ratio (TTM)
UnitedHealth Group Incorporated PE Ratio (TTM)

UnitedHealth Group Incorporated pe-ratio-ttm | UnitedHealth Group Incorporated Quote

Garrison Capital Inc. (GARS): This business developer specializing in investments has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 2.1% over the last 60 days.

Garrison Capital Inc. Price and Consensus

Garrison Capital Inc. Price and Consensus
Garrison Capital Inc. Price and Consensus

Garrison Capital Inc. price-consensus-chart | Garrison Capital Inc. Quote

Garrison Capital has a price-to-earnings ratio (P/E) of 7.75 compared with 8.90 for the industry. The company possesses a Value Score of A.

Garrison Capital Inc. PE Ratio (TTM)

Garrison Capital Inc. PE Ratio (TTM)
Garrison Capital Inc. PE Ratio (TTM)

Garrison Capital Inc. pe-ratio-ttm | Garrison Capital Inc. Quote

Colfax Corporation (CFX): This diversified industrial technology company has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 0.4% over the last 60 days.

Colfax Corporation Price and Consensus

Colfax Corporation Price and Consensus
Colfax Corporation Price and Consensus

Colfax Corporation price-consensus-chart | Colfax Corporation Quote

Colfax has a price-to-earnings ratio (P/E) of 9.04, compared with 17.30 for the industry. The company possesses a Value Score of A.

Colfax Corporation PE Ratio (TTM)

Colfax Corporation PE Ratio (TTM)
Colfax Corporation PE Ratio (TTM)

Colfax Corporation pe-ratio-ttm | Colfax Corporation Quote

See the full list of top ranked stocks here

Learn more about the Value score and how it is calculated here.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Garrison Capital Inc. (GARS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.